P<0.001). Serum 14-3-3β protein showed a positive correlation with the percentage of neutrophils and total serum immunoglobulin E, and a negative correlation with conventional ventilatory lung function parameters (P<0.05). Cross-validation of combined indices showed that the combination of 14-3-3β protein, FeNO, and the percentage of predicted value of forced expiratory flow at 75% of lung volume had an area under the curve of 0.948 for predicting asthma, with a sensitivity and specificity of 88.9% and 93.7%, respectively, demonstrating good diagnostic efficacy (P<0.001). The model had the best extrapolation. Conclusions The combination of serum 14-3-3β protein, FeNO, and the percentage of predicted value of forced expiratory flow at 75% of lung volume can significantly improve the diagnostic efficacy for asthma in children. Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(7): 723-729"/>
Diagnostic efficacy of serum 14-3-3β protein combined with fractional exhaled nitric oxide and conventional ventilatory lung function parameters for bronchial asthma in children
Diagnostic efficacy of serum 14-3-3β protein combined with fractional exhaled nitric oxide and conventional ventilatory lung function parameters for bronchial asthma in children
LI Shu-Fang, GUO Guang-En, YANG Yue-Qin, XIONG Xiao-Man, ZHENG Shi-Wei, XIE Xue-Li, ZHANG Yan-Li
Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
Abstract Objective To explore the diagnostic efficacy of serum 14-3-3β protein combined with fractional exhaled nitric oxide (FeNO) and conventional ventilatory lung function parameters in diagnosing bronchial asthma (referred to as "asthma") in children. Methods A prospective study included 136 children initially diagnosed with asthma during an acute episode as the asthma group, and 85 healthy children undergoing routine health checks as the control group. The study compared the differences in serum 14-3-3β protein concentrations between the two groups, analyzed the correlation of serum 14-3-3β protein with clinical indices, and evaluated the diagnostic efficacy of combining 14-3-3β protein, FeNO, and conventional ventilatory lung function parameters for asthma in children. Results The concentration of serum 14-3-3β protein was higher in the asthma group than in the control group (P<0.001). Serum 14-3-3β protein showed a positive correlation with the percentage of neutrophils and total serum immunoglobulin E, and a negative correlation with conventional ventilatory lung function parameters (P<0.05). Cross-validation of combined indices showed that the combination of 14-3-3β protein, FeNO, and the percentage of predicted value of forced expiratory flow at 75% of lung volume had an area under the curve of 0.948 for predicting asthma, with a sensitivity and specificity of 88.9% and 93.7%, respectively, demonstrating good diagnostic efficacy (P<0.001). The model had the best extrapolation. Conclusions The combination of serum 14-3-3β protein, FeNO, and the percentage of predicted value of forced expiratory flow at 75% of lung volume can significantly improve the diagnostic efficacy for asthma in children. Citation:Chinese Journal of Contemporary Pediatrics, 2024, 26(7): 723-729
LI Shu-Fang,GUO Guang-En,YANG Yue-Qin et al. Diagnostic efficacy of serum 14-3-3β protein combined with fractional exhaled nitric oxide and conventional ventilatory lung function parameters for bronchial asthma in children[J]. CJCP, 2024, 26(7): 723-729.
LI Shu-Fang,GUO Guang-En,YANG Yue-Qin et al. Diagnostic efficacy of serum 14-3-3β protein combined with fractional exhaled nitric oxide and conventional ventilatory lung function parameters for bronchial asthma in children[J]. CJCP, 2024, 26(7): 723-729.
Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children[J]. Am J Respir Crit Care Med, 2007, 175(12): 1304-1345. PMID: 17545458. DOI: 10.1164/rccm.200605-642ST.
American Thoracic Society, European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005[J]. Am J Respir Crit Care Med, 2005, 171(8): 912-930. PMID: 15817806. DOI: 10.1164/rccm.200406-710ST.
Jutel M, Mosnaim GS, Bernstein JA, et al. The one health approach for allergic diseases and asthma[J]. Allergy, 2023, 78(7): 1777-1793. PMID: 37119496. DOI: 10.1111/all.15755.
Pelaia C, Vatrella A, Crimi C, et al. Clinical relevance of understanding mitogen-activated protein kinases involved in asthma[J]. Expert Rev Respir Med, 2020, 14(5): 501-510. PMID: 32098546. DOI: 10.1080/17476348.2020.1735365.
Kataki A, Karagiannidis I, Memos N, et al. Host's endogenous caveolin-1 expression is downregulated in the lung during sepsis to promote cytoprotection[J]. Shock, 2018, 50(2): 199-208. PMID: 28957875. DOI: 10.1097/SHK.0000000000001005.
Shilovskiy IP, Kovchina VI, Timotievich ED, et al. Role and molecular mechanisms of alternative splicing of Th2-cytokines IL-4 and IL-5 in atopic bronchial asthma[J]. Biochemistry (Mosc), 2023, 88(10): 1608-1621. PMID: 38105028. DOI: 10.1134/S0006297923100152.
Li F, Huang Y, Huang YY, et al. MicroRNA-146a promotes IgE class switch in B cells via upregulating 14-3-3σ expression[J]. Mol Immunol, 2017, 92: 180-189. PMID: 29101850. DOI: 10.1016/j.molimm.2017.10.023.
Flinkman E, V?h?talo I, Tuomisto LE, et al. Association between blood eosinophils and neutrophils with clinical features in adult-onset asthma[J]. J Allergy Clin Immunol Pract, 2023, 11(3): 811-821.e5. PMID: 36473624. DOI: 10.1016/j.jaip.2022.11.025.
Li J, Gong X. 14-3-3β is necessary in the regulation of polarization and directional migration of alveolar myofibroblasts by lipopolysaccharide[J]. Exp Lung Res, 2020, 46(1/2): 1-10. PMID: 31920140. DOI: 10.1080/01902148.2019.1711464.
31 Global Initiative for Asthma. Pocket guide for asthma management and prevention[EB/OL]. [2023-12-22]. https://ginasthma. org/pocket-guide-for-asthma-management-and-preven-tion/.
Comberiati P, McCormack K, Malka-Rais J, et al. Proportion of severe asthma patients eligible for mepolizumab therapy by age and age of onset of asthma[J]. J Allergy Clin Immunol Pract, 2019, 7(8): 2689-2696.e2. PMID: 31201938. DOI: 10.1016/j.jaip.2019.05.053.